| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | -0.046 | 0.4 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.1 | 0.4 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |